Meritage Pharma is committed to the development of prescription products based on safe and effective molecules for the treatment of gastrointestinal and atopic diseases. Meritage Pharma’s initial product candidate is intended for the treatment of eosinophilic esophagitis, an allergic inflammation of the esophagus.

Meritage Pharma's management team has an established track record of building successful specialty pharmaceutical companies and in identifying and developing novel products for atopic diseases. The company was founded in March 2008 and has raised $33.5 million in Series A financing from Domain Associates, Latterell Venture Partners and The Vertical Group.